Overview

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

Status:
COMPLETED
Trial end date:
2024-04-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the flavor (basic tastes, aroma, texture, mouthfeel) of VNZ/TEZ/D-IVA fixed dose combination (FDC) granules.
Phase:
PHASE1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
deutivacaftor, tezacaftor , vanzacaftor